Peptency Academy · Testing
How a peptide patch is tested: permeation, content and purity
How is a peptide patch tested for permeation, content and purity?
In particular, in vitro performance testing with respect to drug release, adhesion and skin permeation is discussed1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 A 2025 white paper from international stakeholders lists more than twenty critical quality attributes for a microneedle product form. Source sentence
Abstract: more than twenty potential critical quality attributes (CQAs) are identified for the product form.2 J Control Release 2025
Known, not known, contested
Known
- Fracture force per microneedle is a standard mechanical readout: 3.47 N in one semaglutide patch and 0.37 N in another. Source sentence
robust mechanical strength (3.47 N/needle; fracture force)
3 AAPS PharmSciTech 20264 Int J Nanomedicine 2025 - Skin barrier recovery after patch removal is followed by transepidermal water loss: 10 to 12 hours in the exenatide hyaluronate study. Source sentence
transepidermal water loss (TEWL) determinations showed that skin's barrier properties disrupted by MNs recovered within 10-12 h
5 Pharm Res 2014
Not known
- The same search method found no controlled delivery study of a patch without microneedles carrying GHK-Cu, BPC-157 or semaglutide. Source sentence
Query run on 11 November 2026; no controlled study of a flat patch delivering these peptides in the results.
6 PubMed search for transdermal patch without microneedles, 11 November 2026
Contested
Nothing listed yet.
A test sequence for a microneedle patch
- Mechanical strength comes first: fracture force per microneedle, measured by axial compression. Source sentence
resisted axial compression
7 Int J Pharm 20263 AAPS PharmSciTech 2026 - Insertion is checked next, in layered Parafilm M film or in porcine skin. Source sentence
excellent Parafilm M insertion (> 50% at 450 μm depth) ... ex-vivo porcine skin insertion
3 AAPS PharmSciTech 2026 - Release is measured in a dissolution bath or a Franz cell, and skin barrier recovery is followed by transepidermal water loss. Source sentence
The resulting system was placed in a dissolution bath and the release of model molecules was evaluated.
8 Int J Pharm 20165 Pharm Res 2014 - Permeation goes through excised skin in a diffusion cell with a receptor solution that holds sink conditions. Source sentence
The receptor solution should provide solubility sink conditions throughout the experiment
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - Content per patch comes from extracting the peptide from the microneedles and assaying it. Source sentence
An accurate and reliable method was established to determine the needle drug loading proportion in sCT-DMNAs.
9 AAPS PharmSciTech 2020 - Purity and identity of that extract are then read like any other peptide sample: HPLC area percent for purity and mass spectrometry for identity. Source sentence
The peptide purity was quantified through normalization by calculating the area (UV) of the most abundant peak as a percentage of total peak areas.
10 J Pharm Anal 2015
What the EMA guideline asks of a transdermal patch
- In vitro permeation work normally uses diffusion cells with 0.5 to 2 cm² of skin. The most common design is the Franz type static cell with two chambers. Source sentence
In vitro permeation studies are usually performed using diffusion cells, with a skin diffusion area between 0.5-2 cm2. ... The most common diffusion cells are Franz-type (static) cells
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - The guideline recommends human skin from the torso, meaning breast, abdomen or back, or from a site relevant to the intended use. Source sentence
It is recommended to use human skin from the torso (breast, abdomen or back) or relevant to the site
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - The receptor solution has to keep sink conditions, leave the skin intact, and keep the active substance stable for the whole test. Source sentence
The receptor solution should not affect skin integrity. ... The active substance should be stable in the receptor solution for the duration of the test
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - Patches usually hold more active substance than they deliver, so loading and delivered amount are different numbers. Source sentence
Transdermal patches usually contain an excess of active substance than that delivered
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
What microneedle patches add
- Because biological skin varies, one group proposed Parafilm M layers as a test membrane. A 196 microneedle array with 600 µm microneedles released between 40 and 180 µg of cargo in 6 hours. Source sentence
Dissolving MN arrays containing 196 needles (600 μm needle height) were inserted into a single layer of PF ... releasing between 40 and 180 μg of their cargos after 6h.
8 Int J Pharm 2016 - In that work the Parafilm pouch and a Franz cell gave comparable release curves. Source sentence
the use of PF membrane was tested either in the hermetic "pouch" and using Franz Cell methodology yielding comparable release curves
8 Int J Pharm 2016 - It flags delivered amount and puncture performance as attributes that will need bespoke test methods, and dissolution as a method that needs major adaptation. Source sentence
Abstract, final sentences: the most pertinent attributes will likely require bespoke test methods or major adaptions to established compendial test methods (dissolution).
2 J Control Release 2025 - Variability of the amount delivered into skin was under 6.8 percent for the pure tip liraglutide patch, from 0.93 ± 0.04 mg delivered. Source sentence
Abstract: the patch could deliver up to 0.93 ± 0.04 mg of liraglutide into skin with a variability of less than 6.8%.
11 Drug Deliv Transl Res 2025
What a patch certificate line could look like
- Peptide content per patch
- Method
- Extraction from the microneedle array, then HPLC assay
- Reports
- Mass of peptide per patch
- Purity of the extract
- Method
- HPLC, UV chromatography, area normalisation
- Reports
- Main peak area percent
- Identity of the extract
- Method
- LC-MS
- Reports
- Observed mass against theoretical mass
- Fracture force
- Method
- Axial compression of the microneedles
- Reports
- Force per microneedle
- Insertion
- Method
- Multi-layer Parafilm M film
- Reports
- Percent of layers pierced at each depth
- In vitro release
- Method
- Dissolution bath or Franz cell
- Reports
- Cumulative amount released over time
Terms in patch testing
- Franz cell
- A Franz cell is a two chamber diffusion cell. Skin sits between a donor chamber that holds the patch and a receptor chamber that is sampled over time. Source sentence
The most common diffusion cells are Franz-type (static) cells, which consist of two chambers that can be side-by-side or
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - Sink conditions
- Sink conditions: the receptor solution can dissolve the active so well that the receptor never limits permeation. Source sentence
An acceptable sink ... the permeation of the active substance is not limited by the receptor medium
1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - Critical quality attribute
- Critical quality attribute: a property of the finished product that has to stay in a defined range for quality to hold. Source sentence
Abstract: more than twenty potential critical quality attributes (CQAs) are identified for the product form.
2 J Control Release 2025 - Transepidermal water loss
- Transepidermal water loss: a measure of skin barrier function, used to follow how fast skin recovers after microneedles. Source sentence
transepidermal water loss (TEWL) determinations showed that skin's barrier properties disrupted by MNs recovered within 10-12 h
5 Pharm Res 2014 - Relative bioavailability
- Relative bioavailability compares exposure from a patch with exposure from a reference route, for example 69.8 percent in rats for the liraglutide patch. Source sentence
achieved relative bioavailability of 69.8% and 46.3% compared to S.C. injection in rats and minipigs, respectively
11 Drug Deliv Transl Res 2025
Purity is not content, for a patch too
- HPLC purity is the area of the main peak as a percentage of the total peak area in a UV chromatogram of the sample, so it describes the extract and not the amount of peptide. Source sentence
The peptide purity was quantified through normalization by calculating the area (UV) of the most abundant peak as a percentage of total peak areas.
10 J Pharm Anal 2015 - An accurate extraction and assay method for the loading in the microneedle tips was established for a salmon calcitonin array. Source sentence
An accurate and reliable method was established to determine the needle drug loading proportion in sCT-DMNAs.
9 AAPS PharmSciTech 2020
What is a Franz cell?
The most common diffusion cells are Franz-type (static) cells, which consist of two chambers that can be side-by-side or1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
Why does Parafilm appear in microneedle tests?
The use of biological tissues in the in vitro assessments ... presents some fundamental difficulties, in part due to inherent variability of the biological tissues employed.8 Int J Pharm 2016
What is the difference between loading and delivered amount?
29 ± 2 μg semaglutide per patch, with an apparent delivered amount of 18 ± 2 μg (63 ± 3%; n = 3)7 Int J Pharm 2026
What does a peptide patch certificate of analysis report?
Lab results page: HPLC purity, LC-MS identity, net content.12 Peptency lab results and certificate of analysis page10 J Pharm Anal 20152 J Control Release 2025
Published examples with IDs
Analytical only (no biological model)International journal of pharmaceutics 2016
Release of model cargos from 196 microneedle arrays over 6 hours
- Design
- Parafilm M pouch release test compared with Franz cell methodology for dissolving arrays
- Population or model
- Parafilm M membrane
- Molecule
- Model cargos not established
Analytical only (no biological model)Journal of controlled release : official journal of the Controlled Release Society 2025
Classification, nomenclature and more than twenty critical quality attributes
- Design
- White paper by international stakeholders on regulatory science of microneedle product forms
- Molecule
- Microneedle product forms not established
In vitro or ex vivoAAPS PharmSciTech 2026
Fracture force, Parafilm insertion depth, release over 12 hours and ex vivo porcine skin insertion
- Design
- Formulation and characterisation of dissolving microneedles with hyaluronic acid, PETOX and L-arginine
- Population or model
- Parafilm M, porcine skin ex vivo
- Molecule
- Semaglutide exact
RodentInternational journal of pharmaceutics 2026
Loading per patch, apparent delivered amount, release within 30 minutes and skin barrier recovery
- Design
- Polyvinyl alcohol dissolving microneedles made by vacuum assisted molding, tested in rat skin
- Population or model
- Rats
- Molecule
- Semaglutide exact
- n
- 3
- Comparator
- Unloaded microneedle controls
RodentDrug delivery and translational research 2025
Loading up to 2.21 mg per 0.9 cm², delivered amount, relative bioavailability and local skin response
- Design
- Dissolving microneedle patch with pure drug tips, pharmacokinetics in rats and minipigs
- Population or model
- Rats and minipigs
- Molecule
- Liraglutide related form
Sources
- 1EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 accessed 11 Nov 2026
- 2J Control Release 2025 accessed 11 Nov 2026
- 3AAPS PharmSciTech 2026 accessed 11 Nov 2026
- 4Int J Nanomedicine 2025 accessed 11 Nov 2026
- 5Pharm Res 2014 accessed 11 Nov 2026
- 6PubMed search for transdermal patch without microneedles, 11 November 2026 accessed 11 Nov 2026
- 7Int J Pharm 2026 accessed 11 Nov 2026
- 8Int J Pharm 2016 accessed 11 Nov 2026
- 9AAPS PharmSciTech 2020 accessed 11 Nov 2026
- 10J Pharm Anal 2015 accessed 11 Nov 2026
- 11Drug Deliv Transl Res 2025 accessed 11 Nov 2026
- 12Peptency lab results and certificate of analysis page accessed 11 Nov 2026
About this page
Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
Reviewed by the Peptency editorial process. Version 1, edited 11 November 2026, 12 sources.
Cite this page: Peptency Academy. How a peptide patch is tested: permeation, content and purity. Version 1./eu/academy/testing/how-a-peptide-patch-is-tested/